Phase 3Completed
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial
- Sponsor
- PrECOG, LLC. (Academic or other)
- Enrolment
- 214 enrolled
- Conditions
- Mesothelioma; Pleural Mesothelioma; Malignant Pleural Mesothelioma
- Interventions
- Durvalumab; Standard Chemotherapy; Ipilimumab and Nivolumab
- Ages
- adults, older adults
- Registry
- NCT04334759
Full record on ClinicalTrials.gov
From the registry
Patients with pleural mesothelioma (PM) that cannot be surgically removed will receive standard chemotherapy (cisplatin or carboplatin and pemetrexed) given with durvalumab, a type of immunotherapy, or a treatment chosen by the study doctor, which is either standard chemotherapy or immunotherapy combination (ipilimumab and nivolumab). Durvalumab is an antibody (a type of human protein) that works by blocking a body substance called Programmed Death-Ligand 1 (PD-L1). Blocking PD-L1 helps the body's immune system attack cancer cells. Research has shown that durvalumab can slow tumor growth and shrink tumors in some people with cancer. Previous studies of combining durvalumab and chemotherapy showed that this combination is active in advanced mesothelioma. The purpose of this study is to see whether adding durvalumab to standard chemotherapy will improve overall survival (OS) in patients with PM.
Primary outcomes
- Median Overall Survival (OS)
History
Results first posted
Last registry update
Study completion
Primary completion
Started
Registered